The Cost of the Cure: Policy Issues in the Development and Adoption of Biomarkers
Developing a targeted cancer drug that perfectly attacks a specific genetic mutation is useless if the diagnostic test required to find that mutation is too inaccurate, too expensive, or unapproved by insurance. Policy Issues in the Development and Adoption of Biomarkers for Molecularly Targeted Cancer Therapies is a brutally analytical, highly systemic policy manual detailing exactly how this bottleneck kills patients. This volume provides the precise regulatory blueprints required to force life-saving diagnostics through the bureaucracy of modern healthcare.
Mastering the Companion Diagnostic
The core philosophy of this text is the mandatory pairing of drug and test. The authors aggressively detail the FDA regulatory pathways. It dictates exactly why a pharmaceutical company cannot get a billion-dollar targeted drug (like a BRAF inhibitor) approved without simultaneously validating a flawless genetic test (a biomarker assay) that proves which patients actually have the BRAF mutation, preventing the drug from being wasted on patients it cannot help.
Navigating the Reimbursement Crisis
The book provides a masterclass in health economics. It dictates the exact systemic pathways of clinical adoption. It rigorously explores the maddening reality that Medicare will often pay ,000 for the cancer drug, but initially refuse to pay ,000 for the Next-Generation Sequencing (NGS) panel required to find the mutation, providing the economic models required to prove that the test actually saves the system millions of dollars.
Frequently Asked Questions (FAQs)
Is this a laboratory manual detailing how to run a PCR machine?
No, it is a highly specialized *health policy, regulatory economics, and clinical implementation textbook* focused entirely on the systemic barriers to precision medicine.
Who is the primary audience?
It is an essential, mandatory strategic guide for FDA Regulators, Health Economists, Pathology Directors, Pharmaceutical Executives, and Oncology Policymakers.
